Next 10 |
2024-06-03 16:37:41 ET More on Alzamend Neuro Alzamend Neuro enters private placement of up to $25M Alzamend Neuro terminates at-the-market equity offering program Seeking Alpha’s Quant Rating on Alzamend Neuro Read the full article on Seeking Alpha ...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical compa...
2024-05-09 09:56:45 ET More on Alzamend Neuro Alzamend Neuro terminates at-the-market equity offering program Seeking Alpha’s Quant Rating on Alzamend Neuro Historical earnings data for Alzamend Neuro Financial information for Alzamend Neuro ...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
2024-05-07 08:16:42 ET More on Alzamend Neuro Seeking Alpha’s Quant Rating on Alzamend Neuro Historical earnings data for Alzamend Neuro Financial information for Alzamend Neuro Read the full article on Seeking Alpha For further details see: ...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
2024-03-26 05:52:55 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alzamend Neuro (NASDAQ: ALZN ) just reported results for the third quarter of 2024. Alzamend Neuro reported earnings per share of -38 cents. This was below the analyst est...
X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...
2023-12-18 12:03:34 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alzamend Neuro (NASDAQ: ALZN ) just reported results for the second quarter of 2024. Alzamend Neuro reported earnings per share of -44 cents. The company did not repor...
News, Short Squeeze, Breakout and More Instantly...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...
Investor had agreed to purchase up to $25 million of preferred shares Alzamend expects to use proceeds to further its clinical trials and working capital purposes Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical compa...
Alzamend Neuro, Inc. (Nasdaq: ALZN) (“ Alzamend ”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“ Alzheimer’s ”), bipolar disorder (“ BD ”), major de...